Literature DB >> 27769809

Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease.

Uma Mahadevan1, Ryan A McConnell2, Christina D Chambers3.   

Abstract

The management of the pregnant patient with inflammatory bowel disease is complicated by multiple providers, misinformation, and a disease entity that, particularly when active, can adversely affect pregnancy outcomes. This article seeks to frame the debate on medication safety in pregnancy and lactation using the US Food and Drug Administration's new Pregnancy and Lactation Labeling Rule and the most up-to-date safety information to discuss the risks and benefits of using each class of inflammatory bowel disease medication.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti−Tumor Necrosis Factor; Inflammatory Bowel Disease; Pregnancy

Mesh:

Substances:

Year:  2016        PMID: 27769809     DOI: 10.1053/j.gastro.2016.10.013

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

1.  Gestational Weight Gain: A New Factor Influencing Pregnancy Outcomes in Women with Inflammatory Bowel Disease.

Authors:  Sonia Friedman
Journal:  Dig Dis Sci       Date:  2017-08       Impact factor: 3.199

2.  Overview of Pregnancy in Patients With Inflammatory Bowel Disease.

Authors:  Uma Mahadevan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-02

Review 3.  Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.

Authors:  H Matthew Cohn; Maneesh Dave; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

Review 4.  The Placental Barrier: the Gate and the Fate in Drug Distribution.

Authors:  Nino Tetro; Sonia Moushaev; Miriam Rubinchik-Stern; Sara Eyal
Journal:  Pharm Res       Date:  2018-02-23       Impact factor: 4.200

Review 5.  First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician.

Authors:  Shannon Chang; David Hudesman
Journal:  Curr Gastroenterol Rep       Date:  2020-01-30

Review 6.  Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease.

Authors:  Wendy A Goodman; Ian P Erkkila; Theresa T Pizarro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-09-08       Impact factor: 46.802

7.  Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare.

Authors:  Kenneth D Allen; Miranda K Kiefer; Madalina Butnariu; Anita Afzali
Journal:  Arch Gynecol Obstet       Date:  2022-03-06       Impact factor: 2.344

Review 8.  Thiopurine pharmacogenomics and pregnancy in inflammatory bowel disease.

Authors:  Akira Andoh; Masahiro Kawahara; Takayuki Imai; Goichi Tatsumi; Osamu Inatomi; Yoichi Kakuta
Journal:  J Gastroenterol       Date:  2021-07-21       Impact factor: 7.527

Review 9.  Management of Crohn Disease: A Review.

Authors:  Kelly Cushing; Peter D R Higgins
Journal:  JAMA       Date:  2021-01-05       Impact factor: 157.335

10.  Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants.

Authors:  Michael G Kattah; Jeffrey M Milush; Trevor Burt; Robert P McCabe; Michael I Whang; Averil Ma; Uma Mahadevan
Journal:  Clin Transl Gastroenterol       Date:  2018-04-03       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.